Previous Article | Next Article 
Antimicrobial Agents and Chemotherapy, April 1998, p. 895-898, Vol. 42, No. 4
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
Impact of Bacterial Biofilm Formation on In Vitro
and In Vivo Activities of Antibiotics
Silvia
Schwank,1
Zarko
Rajacic,2
Werner
Zimmerli,2 and
Jürg
Blaser1,*
Department of Internal Medicine, University
Hospital Zurich, Zurich,1 and
Department
of Internal Medicine, University Hospital Basel,
Basel,2 Switzerland
Received 4 August 1997/Returned for modification 16 December
1997/Accepted 24 January 1998
 |
ABSTRACT |
The impact of bacterial adherence on antibiotic activity was
analyzed with two isogenic strains of Staphylococcus
epidermidis that differ in the features of their in vitro biofilm
formation. The eradication of bacteria adhering to glass beads by
amikacin, levofloxacin, rifampin, or teicoplanin was studied in an
animal model and in a pharmacokinetically matched in vitro model. The features of S. epidermidis RP62A that allowed it to grow on
surfaces in multiple layers promoted phenotypic resistance to
antibiotic treatment, whereas strain M7 failed to accumulate, despite
initial adherence on surfaces and growth in suspension similar to those for RP62A. Biofilms of S. epidermidis M7 were better
eradicated than those of strain RP62A in vitro (46 versus 31%;
P < 0.05) as well as in the animal model (39 versus
9%; P < 0.01).
 |
INTRODUCTION |
Antibiotic therapy against an
established biofilm often fails without removal of the infected
implant, despite the use of drugs which are highly active in standard
in vitro susceptibility tests (8). In contrast to antibiotic
therapy of many bacterial infections, standard in vitro susceptibility
tests are not predictive of the therapeutic outcome of device-related
infections (26).
Adhesion to biomaterials is assumed to be a crucial step in the
pathogenesis of foreign body-related infections. Staphylococcus epidermidis represents the most prominent organism responsible for
device-related infections (12, 19), and most S. epidermidis strains are able to attach to polymer surfaces, albeit
with quantitative differences between strains (6, 10, 17,
24). Two phases can be kinetically differentiated during the
establishment of a biofilm, as documented by scanning electron
microscopy. A rapid initial attachment of S. epidermidis
cells to the polymer surface is later followed by the accumulation of
cells in multilayered cell clusters and glycocalyx production
(18). The findings of different investigators suggest that
extracellular slime does not play an important role in the early phase
of attachment of coagulase-negative staphylococci to a biomaterial
surface (7, 10, 17, 23). Colonization of foreign bodies by
coagulase-negative staphylococci is likely to be a dynamic process, and
the factors that mediate initial bacterial adherence may not be the
same as those favoring bacterial persistence, multiplication, and
ultimately, clinical infection.
The present study focuses on the impact of bacterial adherence on the
in vivo and in vitro activities of antibiotics by considering a pair of
isogenic strains that differ with respect to the features of their
accumulation on surfaces. In particular, it was the aim of the study
(i) to observe the impact of differences in bacterial biofilm formation
on the phenotypic resistance of S. epidermidis to the
bactericidal activity of antibiotics and (ii) to compare the results
obtained with an animal model (30) and those obtained with
an in vitro model (25) of treatment of bacterial biofilms with antimicrobial agents.
 |
MATERIALS AND METHODS |
Bacteria.
Two strains of S. epidermidis have been
used: a well-described adherence-positive wild-type strain (S. epidermidis RP62A [ATCC 35984] [4, 14, 15]) and
its adherence-negative mutant (S. epidermidis M7, described
by Schumacher Perdreau et al. [21]).
Drug susceptibility.
MICs and minimum bactericidal
concentrations (MBCs) were determined with both suspended and adherent
bacteria. MICs were determined in both (i) tryptic soy broth (TSB;
Difco Laboratories, Detroit, Mich.) supplemented with 50 µg of
Ca2+ per ml and 25 µg of Mg2+ per ml (TSB-S)
and (ii) phosphate-buffered saline (PBS)-GCP (PBS-GCP is 2.38 g of
Na2HPO4, 0.19 g of
KH2PO4, 8.0 g of NaCl, 0.9 g of glucose, 1.0 g of Casamino Acids, and distilled water to 980.0 ml,
which was separately autoclaved; 20.0 ml of sterile human plasma was
then added to the mixture). The suspended bacteria were tested by a
macrodilution method with a standard inoculum of 106 CFU/ml
(1). MBCs were determined as described by Amsterdam (2). The lowest antibiotic concentration that reduced the
inoculum by
99.9% was defined as the MBC. The susceptibility of
adherent bacteria was tested by a previously described macrodilution
method (25, 29) with an inoculum of 5.5 × 105 CFU/bead. The MBCs were the lowest antibiotic
concentrations that killed
99.9% of the adherent bacteria.
Animal model.
The previously described guinea pig tissue
cage model was used (30). In brief, four sterile
polytetrafluoroethylene (Teflon) tubes (32 by 10 mm) perforated with
130 regularly spaced 1-mm-diameter holes (Ciba-Geigy Ltd.) were each
filled with six sinter-glass beads (Sikug 023/300 A; Schott Schleifer
AG, Muttenz, Switzerland) and were aseptically implanted in the flanks
of albino guinea pigs (weight, 600 to 1,100 g). Experiments started
after complete healing of the wound (3 weeks after surgery). Prior to
each experiment, the interstitial fluid that accumulated in the tissue
cages was checked for sterility. Tissue cages were infected by local
inoculation of about 107 CFU. Antibiotic therapy was
started 16 h after inoculation. At this time the number of
suspended bacteria averaged 5.99 ± 0.3 log10 CFU/ml
for strain M7 and 6.02 ± 0.44 CFU/ml for strain RP62A. The
kinetics of each drug were measured in 10 to 12 tissue cage fluid
samples from three animals. The kinetics were determined at up to seven
time points (time zero to 24 h). In this report only the peak and
the trough levels are given. The average time course of the measured
concentrations was used as a reference to stimulate the kinetics in
vitro. Therefore, pharmacokinetic measurements were performed for a
total of 12 animals.
In vitro model.
A previously described one-compartment
pharmacokinetic model was used in the present study (22,
25). This model allows periodic assessment of the bactericidal
effect of antibiotic dosing against both adherent and suspended
bacteria. A peristaltic pump continuously transported sterile culture
medium from the reservoir into the 17-ml culture compartment resulting
in an exponential decrease in the drug concentration. The bacteria were
exposed in the model to oscillating drug levels simulating the kinetics determined in the cages implanted in the animals.
The system was filled with a special culture medium referred to here as
PBS-GCP. In contrast to standard culture medium this medium supports
growth at only a limited rate and results in a reduced final bacterial
density. The generation time in this medium was 64 min for strain M7
and 81 min for strain RP62A, whereas a generation time of 26 min was
observed for both strains in TSB.
The intention was to achieve in the in vitro model an inoculum of
suspended bacteria with numbers similar to the numbers in vivo at the
onset of treatment. To obtain such an in vitro inoculum, glass beads
were exposed to the bacteria in a flask for 16 h before the onset
of treatment. This simulated the 16-h delay between in vivo inoculation
and the start of therapy. Sterile sinter-glass beads (Sikug 023/300 A;
Schott Schleifer AG) were placed for 16 h in a bacterial
suspension of 25 ml of PBS-GCP inoculated with three bacterial colonies
taken from a blood agar plate (working cultures). The beads covered
with bacterial biofilm were separated from the PBS-GCP of the overnight
culture by filtration and were rinsed with 10 ml of sterile saline
solution to wash off the bacteria suspended within the broth carried
over from the culture. Subsequently, 10 beads were placed into the
culture compartment with a sterile surgical forceps 30 min before the
start of antibiotic treatment. The inocula in the suspensions in the
model present at the beginning of antibiotic dosing averaged 5.61 ± 0.37 and 5.20 ± 0.26 log10 CFU/ml for strains M7
and RP62A, respectively. The number of adherent bacteria per glass bead
averaged 5.91 ± 0.48 and 5.65 ± 0.25 log10 CFU/bead for strains M7 and RP62A, respectively. Control experiments demonstrated stationary-phase conditions. The number of suspended bacteria as well as the number of adherent bacteria of both strains did
not change by more than 0.66 log over an incubation period of 48 h
in the in vitro model. Each drug and both strains have been tested with
three animals with four tissue cages containing a total of 24 beads.
The numbers of CFU in one animal were determined at the beginning of
the treatment, and the numbers of CFU in a second animal not treated
with an antibiotic were determined at the same time point. Since only
the data for animals with complete eradication of all microorganisms
are reported (see Table 2), the data for the control animals are not
presented. Overall, drug efficacy was evaluated with 24 animals (3 animals per drug and strain). Since each bead was processed separately
72 individual microbiological determinations were performed per drug
and strain. Due to the need to restrict the use of animals, we believe
that it would not have been justified to use more animals.
Antibiotic concentrations and dosage regimens.
Table
1 summarizes the dosing of the
antibiotics in vivo and the concentrations achieved in serum and tissue
cage fluid. The kinetics of each drug have been measured in 10 to 12 tissue cage fluid samples from three animals. The kinetics were
determined at up to seven time points (time zero to 24 h). In this
report only the peak and trough levels are given. The average time
course of the measured concentrations was used as a reference to
simulate the kinetics in vitro. Therefore, pharmacokinetic measurements were obtained for a total of 12 animals. The peak and trough
concentrations obtained in vitro are also listed. The concentrations
determined in the samples from the animals in the in vivo study were
determined in antibiotic medium 1 (Difco Laboratories) by agar
diffusion bioassays. Bacillus subtilis 0453-52-9 (Difco) was
used as the test strain. Standard curves were generated from pooled
heat-inactivated guinea pig serum with a final concentration of 50%.
Results were calculated by microcomputer-assisted exponential
regression analysis (Hewlett-Packard HP41V). The concentrations
achieved in vitro were defined according to the concentrations obtained
in vivo in the infected tissue cages. A one-compartment kinetic model was simulated in vitro on the basis of the in vivo observations over
the two 12-h dosing intervals (Table 1). Concentration-time profiles
for all four drugs were calculated, and the presence of the calculated
concentration profiles within the culture compartments was confirmed by
spectrophotometric concentration measurements by using fluorescein
sodium as the test substance (PBS [pH 7.4], 23°C, 490 nm;
r2 = 0.9996; Stasar III; Gilford Instrument
Laboratories Inc., Oberlin, Ohio). The kinetics of the in vitro system
were determined every 0.5 h over the entire dosing interval. The
mean intra-assay and interassay coefficients of variation were less
than 5%; the measured concentrations of all four drugs averaged 101% ± 5% of the respective target values.
Quantification of bactericidal activity. (i) In vivo.
Six
beads were removed from each cage at each sampling point. The number of
bacteria adhering to the beads was determined as described previously
(29). Each bead was placed on a filter with a sterile
forceps and was washed twice with saline. The number of bacteria
adhering to the beads was determined by placing the washed glass beads
in 2 ml of physiological saline containing EDTA (0.15%) and Triton
X-100 (0.1%), followed by vigorous vortexing three times for 15 s
each time to remove the adhering bacteria. Thereafter, the tubes were
placed in an ultrasonic bath and sonicated for 3 min at 120 W (Labsonic
2000; Bender & Hobein, Zurich, Switzerland). The specimens containing
resuspended bacteria were subsequently diluted 100- to 10,000-fold and
were subcultured at 37°C onto tryptic soy agar plates. The detection
limit was 20 CFU per bead. The term "sterile" is defined here as no
bacterial growth in subcultures of individual beads.
(ii) In vitro.
Each bead was removed from the compartment
after 24 h of antibiotic treatment. The bacteria adhering to the
sinter-glass bead were detached by vortexing as described previously
(25). The detection limit was 40 CFU per bead. The term
"sterile" is defined here as no bacterial growth in subcultures of
individual beads.
Data analysis.
Probabilities (P values) of <0.05
were considered statistically significant. The chi-square test was used
for analysis of the frequency of bacterial eradication.
 |
RESULTS |
Antibiotic efficacy against adherent bacteria.
In vivo
S. epidermidis M7 was eradicated from 37 of 96 beads (39%),
whereas S. epidermidis RP62A was eradicated from 9 of 96 beads (9%) (P < 0.01) (Table
2). The difference between the eradication of the two strains was less pronounced in vitro but was
still statistically significant (46 of 100 versus 31 of 100 beads;
P < 0.05). In vivo, rifampin eradicated both strains
of glass bead-adherent bacteria more frequently than each of the other
three drugs (P < 0.05), (Table 2). Compared to the in
vitro activities of the other three drugs, rifampin was most efficient against strain RP62A (P < 0.05) (Table 2). Compared to
rifampin, levofloxacin was insignificantly less active in vitro against strain M7 but was considerably less active against strain RP62A (P < 0.05).
View this table:
[in this window]
[in a new window]
|
TABLE 2.
Eradication of adherent bacteria of two isogenic strains
of S. epidermidis in an in vitro and in an in vivo model
|
|
Impact of culture medium and bacterial adherence on MBCs.
The
susceptibilities of both strains were determined by the MIC
macrodilution method as well as by four different MBC methods (Table
3). Only limited differences were
observed between the MBCs determined in TSB and those determined in
PBS-GCP for either suspended or adherent pathogens. However, major
differences were noted in a comparison of the MBCs for adherent and
suspended bacteria, particularly with rifampin and teicoplanin. The
poor activity of amikacin in both the in vivo and the in vitro models
reflected the fact that peak levels in the culture compartments were
consistently lower than the MICs and MBCs for both strains (Tables 1
and 3). In contrast, the concentrations of the other three compounds in the culture compartments were above the MICs and MBCs determined for
suspended bacteria for almost the entire dosing interval. The peak
levels but not the trough levels of levofloxacin were above the MBCs
determined for adherent bacteria. Similarly, the peak levels but not
the trough levels of rifampin were above the MBC for the adherent
bacteria determined in PBS-GCP. For teicoplanin even the peak levels
were below the MBCs for the adherent bacteria determined in PBS-GCP and
in TSB-S.
 |
DISCUSSION |
This study shows an impaired antimicrobial eradication of a
biofilm-forming strain of S. epidermidis compared to the
antimicrobial eradication of its biofilm-negative mutant. This
phenotypic resistance relates to a multilayered growth on surfaces and
was observed despite similar initial levels of adherence on surfaces
and similar levels of growth in suspension. The significance of
adherent growth of coagulase-negative staphylococci has previously been
assessed both in vitro and in an endocarditis model (20,
27). The in vitro study considered various culture conditions
that closely mimic the clinical situation with both important clinical
isolates and isolates from the skin of volunteers (27). The
in vivo study considered the pair of isogenic strains used in the
present study (20). In both investigations, the isolates
that exhibited accumulative growth when cultured in TSB did not differ
with respect to biofilm formation when cultured in the presence of
serum. In contrast, the data obtained in the present study suggest that
despite the addition of serum to the culture medium, differences in the
bactericidal activities of antimicrobial agents can be detected in vivo
as well as in vitro.
The enhanced activities of levofloxacin and rifampin compared with the
activities of the two other drugs in both the in vivo and the in vitro
models are consistent with increased ratios of peak concentrations
versus MBCs for adherent bacteria. The MBCs were comparable to the
average concentrations obtained in the cages and culture compartments.
The MICs and MBCs determined for suspended bacteria were less
predictive for the assessment of efficacy in both models. These
findings are consistent with those of previous studies documenting that
successful treatment of experimental device-related infections cannot
be predicted when the trough antibiotic levels exceed the MIC at the
site of infection (29). In contrast, in vivo efficacy was
predicted if the MBC for the organism in the stationary phase was in
the susceptible range and if glass-adherent staphylococci were killed
by low drug concentrations.
An interesting difference was noted when comparing the MBCs for
suspended bacteria versus those for adherent bacteria for both strains.
In contrast to amikacin, rifampin, and teicoplanin, the in vitro
activity of levofloxacin was compromised only to a very limited extent
by bacterial adherence. The reasons for this observation are not clear.
A recent investigation that considered the same isogenic strains of
S. epidermidis used in this study provided biochemical and
functional evidence that a 140-kDa protein present in extracellular material plays a role in the accumulative growth of S. epidermidis RP62A (11). This protein is lacking in
mutant M7. The protein could be isolated only by using sessile growth
conditions, possibly reflecting an important property of staphylococci,
that is, that they can rapidly change specific phenotypic features
(phase variants) (4). Various factors that contribute to the
primary attachment of S. epidermidis cells to surfaces have
been described and isolated. Among these factors, the capsular
polysaccharide adhesin (16, 24), the slime-associated
antigen (3, 5), and the polysaccharide intercellular adhesin
(9, 13, 28) are of particular interest. One may ask of what
importance these factors are, considering the impact of culture
conditions and recognizing the fact that bacterial growth and
persistence must occur in vitro as well as in vivo in changing, hostile
environments. So far, the significance of these factors studied either
in vitro or ex vivo has not yet been sufficiently documented in a
clinical context. Further studies are needed to evaluate a possible
correlation between the presence of these factors and the severity of
device-associated infections. Only a limited number of investigations
have assessed the isolated effects of specific factors in animal
models, and even fewer data on the significance of these factors for
antibiotic therapy are available.
In conclusion, the findings presented here suggest that differences in
the accumulative growth on surfaces may present themselves as
phenotypic resistance to antibiotic treatment of biofilm-forming S. epidermidis.
 |
ACKNOWLEDGMENTS |
We are indebted to G. Peters for providing S. epidermidis RP62A and M7 and to Hoechst Pharma AG (A. Steinbach)
for an educational grant.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Medicine, D POL 40, University Hospital Zurich, Rämistrasse 100, CH-8091 Zurich, Switzerland. Phone: 41-1-255-3618. Fax: 41-1-255-4562. E-mail: dimjbl{at}usz.unizh.ch.
 |
REFERENCES |
| 1.
|
Amsterdam, D.
1996.
Susceptibility testing of antimicrobials in liquid media, p. 73-75.
In
V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, Md.
|
| 2.
|
Amsterdam, D.
1996.
Susceptibility testing of antimicrobials in liquid media, p. 102-103.
In
V. Lorian (ed.), Antibiotics in laboratory medicine, 4th ed. The Williams & Wilkins Co., Baltimore, Md.
|
| 3.
|
Baldassarri, L.,
G. Donnelli,
A. Gelosia,
M. C. Voglino,
A. W. Simpson, and G. D. Christensen.
1996.
Purification and characterization of the staphylococcal slime-associated antigen and its occurrence among Staphylococcus epidermidis clinical isolates.
Infect. Immun.
64:3410-3415[Abstract].
|
| 4.
|
Christensen, G. D.,
L. M. Baddour, and W. A. Simpson.
1987.
Phenotypic variation of Staphylococcus epidermidis slime production in vitro and in vivo.
Infect. Immun.
55:2870-2877[Abstract/Free Full Text].
|
| 5.
|
Christensen, G. D.,
L. P. Barker,
T. P. Mawhinney,
L. M. Baddour, and W. A. Simpson.
1990.
Identification of an antigenic marker of slime production for Staphylococcus epidermidis.
Infect. Immun.
58:2906-2911[Abstract/Free Full Text].
|
| 6.
|
Espersen, F.,
B. J. Wilkinson,
B. Gahrn Hansen,
V. Thamdrup Rosdahl, and I. Clemmensen.
1990.
Attachment of staphylococci to silicone catheters in vitro.
APMIS
98:471-478[Medline].
|
| 7.
|
Fleer, A., and J. Verhoef.
1989.
An evaluation of the role of surface hydrophobicity and extracellular slime in the pathogenesis of foreign-body-related infections due to coagulase-negative staphylococci.
J. Invest. Surg.
2:391-396[Medline].
|
| 8.
|
Gristina, A. G.,
P. Naylor, and Q. Myrvik.
1988.
Infections from biomaterials and implants: a race for the surface.
Med. Prog. Technol.
14:205-224[Medline].
|
| 9.
|
Heilmann, C.,
O. Schweitzer,
C. Gerke,
N. Vanittanakom,
D. Mack, and F. Gotz.
1996.
Molecular basis of intercellular adhesion in the biofilm-forming Staphylococcus epidermidis.
Mol. Microbiol.
20:1083-1091[Medline].
|
| 10.
|
Hogt, A. H.,
J. Dankert, and J. Feijen.
1986.
Adhesion of coagulase-negative staphylococci to methacrylate polymers and copolymers.
J. Biomed. Mater. Res.
20:533-545[Medline].
|
| 11.
|
Hussain, M.,
M. Herrmann,
C. von Eiff,
F. Perdreau Remington, and G. Peters.
1997.
A 140-kilodalton extracellular protein is essential for the accumulation of Staphylococcus epidermidis strains on surfaces.
Infect. Immun.
65:519-524[Abstract].
|
| 12.
|
Kloos, W. E., and T. L. Bannerman.
1994.
Update on clinical significance of coagulase-negative staphylococci.
Clin. Microbiol. Rev.
7:117-140[Abstract/Free Full Text].
|
| 13.
|
Mack, D.,
M. Haeder,
N. Siemssen, and R. Laufs.
1996.
Association of biofilm production of coagulase-negative staphylococci with expression of a specific polysaccharide intercellular adhesin.
J. Infect. Dis.
174:881-884[Medline].
|
| 14.
|
McDermid, K. P.,
D. W. Morck,
M. E. Olson,
M. K. Dasgupta, and J. W. Costerton.
1993.
Effect of growth conditions on expression and antigenicity of Staphylococcus epidermidis RP62A cell envelope proteins.
Infect. Immun.
61:1743-1749[Abstract/Free Full Text].
|
| 15.
|
Mempel, M.,
H. Feucht,
W. Ziebuhr,
M. Endres,
R. Laufs, and L. Gruter.
1994.
Lack of mecA transcription in slime-negative phase variants of methicillin-resistant Staphylococcus epidermidis.
Antimicrob. Agents Chemother.
38:1251-1255[Abstract/Free Full Text].
|
| 16.
|
Muller, E.,
S. Takeda,
H. Shiro,
D. Goldmann, and G. B. Pier.
1993.
Occurrence of capsular polysaccharide/adhesin among clinical isolates of coagulase-negative staphylococci.
J. Infect. Dis.
168:1211-1218[Medline].
|
| 17.
|
Pascual, A.,
A. Fleer,
N. A. Westerdaal, and J. Verhoef.
1986.
Modulation of adherence of coagulase-negative staphylococci to Teflon catheters in vitro.
Eur. J. Clin. Microbiol.
5:518-522[Medline].
|
| 18.
|
Peters, G.,
R. Locci, and G. Pulverer.
1982.
Adherence and growth of coagulase-negative staphylococci on surfaces of intravenous catheters.
J. Infect. Dis.
146:479-482[Medline].
|
| 19.
|
Pfaller, M. A., and L. A. Herwaldt.
1988.
Laboratory, clinical, and epidemiological aspects of coagulase-negative staphylococci.
Clin. Microbiol. Rev.
1:281-299[Abstract/Free Full Text].
|
| 20.
|
Schumacher Perdreau, F.,
H. F. Chambers,
M. H. Wilcox,
G. Peters,
M. Sande, and G. Pulverer.
1993.
Staphylococcus epidermidis wild type and its slime-negative mutant equally induce endocarditis in rabbits, abstr. 148, p. 146.
In
Abstract of the 33rd Interscience Conference on Antimicrobial Agents and Chemotherapy. American Society for Microbiology, Washington, D.C.
|
| 21.
|
Schumacher Perdreau, F.,
C. Heilmann,
G. Peters,
F. Gotz, and G. Pulverer.
1994.
Comparative analysis of a biofilm-forming Staphylococcus epidermidis strain and its adhesion-positive, accumulation-negative mutant M7.
FEMS Microbiol. Lett.
117:71-78[Medline].
|
| 22.
|
Schwank, S., and J. Blaser.
1996.
Once- versus thrice-daily netilmicin combined with amoxicillin, penicillin, or vancomycin against Enterococcus faecalis in a pharmacodynamic in vitro model.
Antimicrob. Agents Chemother.
40:2258-2261[Abstract].
|
| 23.
|
Timmerman, C. P.,
A. Fleer,
J. M. Besnier,
L. De Graaf,
F. Cremers, and J. Verhoef.
1991.
Characterization of a proteinaceous adhesin of Staphylococcus epidermidis which mediates attachment to polystyrene.
Infect. Immun.
59:4187-4192[Abstract/Free Full Text].
|
| 24.
|
Tojo, M.,
N. Yamashita,
D. A. Goldmann, and G. B. Pier.
1988.
Isolation and characterization of a capsular polysaccharide adhesin from Staphylococcus epidermidis.
J. Infect. Dis.
157:713-722[Medline]. (Erratum, 158:268.)
|
| 25.
|
Vergères, P., and J. Blaser.
1992.
Amikacin, ceftazidime, and flucloxacillin against suspended and adherent Pseudomonas aeruginosa and Staphylococcus epidermidis in an in vitro model of infection.
J. Infect. Dis.
165:281-289[Medline].
|
| 26.
|
Widmer, A. F.,
R. Frei,
Z. Rajacic, and W. Zimmerli.
1990.
Correlation between in vivo and in vitro efficacy of antimicrobial agents against foreign body infections.
J. Infect. Dis.
162:96-102[Medline].
|
| 27.
|
Wilcox, M. H., and F. Schumacher Perdreau.
1994.
Lack of evidence for increased adherent growth in broth or human serum of clinically significant coagulase-negative staphylococci.
J. Hosp. Infect.
26:239-250[Medline].
|
| 28.
|
Ziebuhr, W.,
C. Heilmann,
F. Gotz,
P. Meyer,
K. Wilms,
E. Straube, and J. Hacker.
1997.
Detection of the intercellular adhesion gene cluster (ica) and phase variation in Staphylococcus epidermidis blood culture strains and mucosal isolates.
Infect. Immun.
65:890-896[Abstract].
|
| 29.
|
Zimmerli, W.,
R. Frei,
A. F. Widmer, and Z. Rajacic.
1994.
Microbiological tests to predict treatment outcome in experimental device-related infections due to Staphylococcus aureus.
J. Antimicrob. Chemother.
33:959-967[Abstract/Free Full Text].
|
| 30.
|
Zimmerli, W.,
F. A. Waldvogel,
P. Vaudaux, and U. E. Nydegger.
1982.
Pathogenesis of foreign body infection: description and characteristics of an animal model.
J. Infect. Dis.
146:487-497[Medline].
|
Antimicrobial Agents and Chemotherapy, April 1998, p. 895-898, Vol. 42, No. 4
0066-4804/98/$04.00+0
Copyright © 1998, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Robertson, G. T., Bonventre, E. J., Doyle, T. B., Du, Q., Duncan, L., Morris, T. W., Roche, E. D., Yan, D., Lynch, A. S.
(2008). In Vitro Evaluation of CBR-2092, a Novel Rifamycin-Quinolone Hybrid Antibiotic: Studies of the Mode of Action in Staphylococcus aureus. Antimicrob. Agents Chemother.
52: 2313-2323
[Abstract]
[Full Text]
-
Yeater, K. M., Chandra, J., Cheng, G., Mukherjee, P. K., Zhao, X., Rodriguez-Zas, S. L., Kwast, K. E., Ghannoum, M. A., Hoyer, L. L.
(2007). Temporal analysis of Candida albicans gene expression during biofilm development. Microbiology
153: 2373-2385
[Abstract]
[Full Text]
-
Trampuz, A., Murphy, C. K., Rothstein, D. M., Widmer, A. F., Landmann, R., Zimmerli, W.
(2007). Efficacy of a Novel Rifamycin Derivative, ABI-0043, against Staphylococcus aureus in an Experimental Model of Foreign-Body Infection. Antimicrob. Agents Chemother.
51: 2540-2545
[Abstract]
[Full Text]
-
Zhao, X., Daniels, K. J., Oh, S.-H., Green, C. B., Yeater, K. M., Soll, D. R., Hoyer, L. L.
(2006). Candida albicans Als3p is required for wild-type biofilm formation on silicone elastomer surfaces.. Microbiology
152: 2287-2299
[Abstract]
[Full Text]
-
Al-Fattani, M. A., Douglas, L. J.
(2006). Biofilm matrix of Candida albicans and Candida tropicalis: chemical composition and role in drug resistance.. J Med Microbiol
55: 999-1008
[Abstract]
[Full Text]
-
Lee, J.-Y., Ko, K. S., Peck, K. R., Oh, W. S., Song, J.-H.
(2006). In vitro evaluation of the antibiotic lock technique (ALT) for the treatment of catheter-related infections caused by staphylococci. J Antimicrob Chemother
57: 1110-1115
[Abstract]
[Full Text]
-
Senn, M. M., Giachino, P., Homerova, D., Steinhuber, A., Strassner, J., Kormanec, J., Fluckiger, U., Berger-Bachi, B., Bischoff, M.
(2005). Molecular Analysis and Organization of the {sigma}B Operon in Staphylococcus aureus. J. Bacteriol.
187: 8006-8019
[Abstract]
[Full Text]
-
Goerke, C., Fluckiger, U., Steinhuber, A., Bisanzio, V., Ulrich, M., Bischoff, M., Patti, J. M., Wolz, C.
(2005). Role of Staphylococcus aureus Global Regulators sae and {sigma}B in Virulence Gene Expression during Device-Related Infection. Infect. Immun.
73: 3415-3421
[Abstract]
[Full Text]
-
Trebse, R., Pisot, V., Trampuz, A.
(2005). Treatment of infected retained implants. J Bone Joint Surg Br
87-B: 249-256
[Abstract]
[Full Text]
-
Zimmerli, W., Trampuz, A., Ochsner, P. E.
(2004). Prosthetic-Joint Infections. NEJM
351: 1645-1654
[Full Text]
-
Kadurugamuwa, J. L., Sin, L. V., Yu, J., Francis, K. P., Kimura, R., Purchio, T., Contag, P. R.
(2003). Rapid Direct Method for Monitoring Antibiotics in a Mouse Model of Bacterial Biofilm Infection. Antimicrob. Agents Chemother.
47: 3130-3137
[Abstract]
[Full Text]
-
Vaudaux, P., Francois, P., Bisognano, C., Li, D., Lew, D. P., Schrenzel, J.
(2003). Comparative efficacy of daptomycin and vancomycin in the therapy of experimental foreign body infection due to Staphylococcus aureus. J Antimicrob Chemother
52: 89-95
[Abstract]
[Full Text]
-
Wolz, C., Goerke, C., Landmann, R., Zimmerli, W., Fluckiger, U.
(2002). Transcription of Clumping Factor A in Attached and Unattached Staphylococcus aureus In Vitro and during Device-Related Infection. Infect. Immun.
70: 2758-2762
[Abstract]
[Full Text]
-
Vaudaux, P., Francois, P., Bisognano, C., Schrenzel, J., Lew, D. P.
(2002). Comparison of Levofloxacin, Alatrofloxacin, and Vancomycin for Prophylaxis and Treatment of Experimental Foreign-Body-Associated Infection by Methicillin-Resistant Staphylococcus aureus. Antimicrob. Agents Chemother.
46: 1503-1509
[Abstract]
[Full Text]
-
Monzon, M., Oteiza, C., Leiva, J., Amorena, B.
(2001). Synergy of different antibiotic combinations in biofilms of Staphylococcus epidermidis. J Antimicrob Chemother
48: 793-801
[Abstract]
[Full Text]
-
O'GARA, J. P., HUMPHREYS, H.
(2001). Staphylococcus epidermidis biofilms: importance and implications. J Med Microbiol
50: 582-587
[Abstract]
[Full Text]
-
Wilcox, M. H., Kite, P., Mills, K., Sugden, S.
(2001). In situ measurement of linezolid and vancomycin concentrations in intravascular catheter-associated biofilm. J Antimicrob Chemother
47: 171-175
[Abstract]
[Full Text]
-
Rachid, S., Ohlsen, K., Witte, W., Hacker, J., Ziebuhr, W.
(2000). Effect of Subinhibitory Antibiotic Concentrations on Polysaccharide Intercellular Adhesin Expression in Biofilm-Forming Staphylococcus epidermidis. Antimicrob. Agents Chemother.
44: 3357-3363
[Abstract]
[Full Text]
-
Veyries, M.-L., Faurisson, F., Joly-Guillou, M.-L., Rouveix, B.
(2000). Control of Staphylococcal Adhesion to Polymethylmethacrylate and Enhancement of Susceptibility to Antibiotics by Poloxamer 407. Antimicrob. Agents Chemother.
44: 1093-1096
[Abstract]
[Full Text]
-
Truninger, K, Jost, C H A., Seifert, B, Vogt, P R, Follath, F, Schaffner, A, Jenni, R
(1999). Long term follow up of prosthetic valve endocarditis: what characteristics identify patients who were treated successfully with antibiotics alone?. Heart
82: 714-720
[Abstract]
[Full Text]